Where does Infinity Pharmaceuticals, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Infinity Pharmaceuticals, Inc. ranks #5,522 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Infinity Pharmaceuticals, Inc. hold?

Infinity Pharmaceuticals, Inc. holds 62 US utility patents granted between 2015 and 2025, spanning 14 technology areas.

What is Infinity Pharmaceuticals, Inc.'s Innovation Score?

Infinity Pharmaceuticals, Inc. has an Innovation Score of 46.1 out of 100 (top 22% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is Infinity Pharmaceuticals, Inc.'s patent grant rate increasing or decreasing?

Infinity Pharmaceuticals, Inc.'s recent grant velocity is -64% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Infinity Pharmaceuticals, Inc.'s patents?

Infinity Pharmaceuticals, Inc.'s patents average 26.1 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Infinity Pharmaceuticals, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Infinity Pharmaceuticals, Inc.

Q: What technology areas does Infinity Pharmaceuticals, Inc. focus on?

Infinity Pharmaceuticals, Inc.'s top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 55 patents. Grants appear in 14 CPC subclasses total.

USPTO PatentsView assignee record - 62 granted patents across 14 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Infinity ranks #5,522 of 49,997 tracked US assignees by granted-patent volume, with 62 patents across 14 technology areas.

#5,522
of 49,997 US assignees by volume: Top 22%
by Innovation Score (46.1/100): 26.1
avg claims per patent: -64%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R5522 · US Corporation #5,522 · 62 grants

GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-FOCUS · INNOV-PAR · CLAIMS-DENSE · TYPE-USCORP · VEL-DROP · BOOK-FULL

GRANTS-SMALL 62 grants
UPPER-Q #5,522/49,997
PHOTO-FINISH IHC Holland IE B V
CPC-FOCUS A61P · 14 areas
INNOV-PAR 46.1/100
CLAIMS-DENSE 26.1 claims/avg
TYPE-USCORP US Corporation
VEL-DROP -64% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: IHC Holland IE B.V. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Qualcomm Incorporated · highest

85
Bauer Maschinen · near

46
Infinity Pharmaceuti… · this assignee

46
Leeb Innovations · near

46
OMS Investments · near

46
Sarepta Therapeutics · near

46
3D Lighting… · lowest

7

What this shows Infinity's Innovation Score is 46.1/100 (top 22% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Where Infinity's grants concentrate

Infinity Pharmaceuticals, Inc. is a focused PatentsView assignee: 14 CPC subclasses with 88.7% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2015 (12 grants) versus a trough of 2 in 2022. By volume, Infinity sits between IHC Holland IE B.V. and Korea Kumho Petrochemical Co., Ltd..

Infinity's three-year grant acceleration

Infinity Pharmaceuticals, Inc. shows 7 grants in 2022–2024 against only 13 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

IHC Holland IE B V

62
Invacare

62
Imagine Communica…

62
Implus Footcare

62
Innova

62
International Aid…

62
Kayaba Industry

62
Korea Kumho Petro…

62
Infinity Pharmace… ◀

62

What this shows Infinity holds 62 patents at rank #5,521, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Infinity

By rank, the assignees closest to #5,521 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Infinity's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Infinity, neither rank-band nor same-CPC leaders (those blocks stay above).

Similar innovation score

Nearest assignees by Innovation Score (46 here).

OMS Investments, Inc. 46 Sarepta Therapeutics, Inc. 46 Leeb Innovations, LLC 46 Bauer Maschinen GmbH 46

Similar claim depth

Nearest assignees by average claims per patent (26.1 here).

Nant Holdings IP, LLC 26.1 avg Milestone Entertainment, LLC 26.1 avg Incyte Corporation 26.1 avg Novozymes, Inc. 26.0 avg

Infinity's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

46 Top 22% higher than 78% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Infinity Pharmaceuticals, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	12	19.4%
2016	11	17.7%
2017	12	19.4%
2018	6	9.7%
2019	4	6.5%
2020	4	6.5%
2021	5	8.1%
2022	2	3.2%
2023	2	3.2%
2024	3	4.8%
2025partial year	1	1.6%

Which technologies does Infinity Pharmaceuticals, Inc. patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 55

C07D - Heterocyclic Compounds 49

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 35

C07J - Steroids 11

A61N - ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy 10

Y02A - Technologies FOR Adaptation TO Climate Change 10

C07F - Acyclic, Carbocyclic OR Heterocyclic Compounds Containing Elements Other Than Carbon, Hydrogen, Halogen, Oxygen, Nitrogen, Sulfur, Selenium OR Tellurium 8

C07B - General Methods OF Organic CHEMISTRY; Apparatus Therefor 6

C07K - Peptides 5

B01J - Chemical OR Physical Processes, e.g. Catalysis OR Colloid CHEMISTRY; Their Relevant Apparatus 3

C12Y - Enzymes 2

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 2

C12P - Fermentation OR Enzyme-using Processes TO Synthesise A Desired Chemical Compound OR Composition OR TO Separate Optical Isomers From A Racemic Mixture 1

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 1

Top 14 of 14 technology areas

Where it ranks

Overall rank by patents

#5,522

of 49,997 tracked assignees

Innovation Score

46.1 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Infinity Pharmaceuticals, Inc.'s patent record in context - here's where to go next.

Infinity Pharmaceuticals, Inc.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 88.7% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #5,522 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Infinity Pharmaceuticals, Inc. against IHC Holland IE B.V., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 46.1/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.